Gotham Asset Management LLC Increases Stock Position in Certara, Inc. (NASDAQ:CERT)

Gotham Asset Management LLC increased its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 590.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 431,326 shares of the company's stock after purchasing an additional 368,821 shares during the quarter. Gotham Asset Management LLC owned 0.27% of Certara worth $4,594,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Barclays PLC boosted its stake in shares of Certara by 198.3% during the third quarter. Barclays PLC now owns 70,525 shares of the company's stock valued at $825,000 after purchasing an additional 46,880 shares during the period. Kopion Asset Management LLC raised its holdings in Certara by 46.0% during the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock valued at $5,918,000 after buying an additional 175,005 shares during the last quarter. Blue Trust Inc. boosted its position in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after buying an additional 822 shares during the period. KBC Group NV boosted its position in Certara by 64.1% during the 4th quarter. KBC Group NV now owns 7,998 shares of the company's stock valued at $85,000 after buying an additional 3,125 shares during the period. Finally, Choreo LLC grew its holdings in Certara by 25.0% in the 4th quarter. Choreo LLC now owns 50,582 shares of the company's stock worth $533,000 after acquiring an additional 10,118 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on CERT. William Blair reaffirmed a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. KeyCorp lifted their price objective on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $11.00 to $14.00 in a report on Thursday, May 8th. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Finally, TD Cowen began coverage on shares of Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Certara currently has an average rating of "Moderate Buy" and an average price target of $15.67.

Certara Stock Down 1.7%

Shares of NASDAQ CERT traded down $0.21 on Tuesday, reaching $11.58. 298,188 shares of the company's stock traded hands, compared to its average volume of 1,307,852. The business's 50 day simple moving average is $11.73 and its two-hundred day simple moving average is $11.75. Certara, Inc. has a 12 month low of $8.64 and a 12 month high of $17.76. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -57.73, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS. As a group, equities research analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.